Resonance Health (ASX:RHT) today announced its wholly-owned subsidiary, Resonance Health Analysis Services, has signed an agreement with the New England Research Institutes (NERI) to provide FerriScan as part of clinical trials into the iron loading disorder thalassemia. The agreement will see FerriScan used by approximately 13 leading clinical sites in the US and other countries over the next four years.
FerriScan will be used to measure liver iron levels in patients with beta-thalassemia. The information provided by FerriScan will assist clinicians to determine the effects of iron overload on organ injury (including the heart), along with enabling the efficacy of new therapies for beta-thalassemia to be monitored. The work will be undertaken on behalf of the Thalassemia Clinical Research Network (TCRN).
Beta-thalassemia is a genetic blood disorder and a very severe and debilitating form of anaemia, resulting in iron overload due to the requirement for frequent blood transfusions.
Patients involved in this program having a FerriScan will no longer need to have a liver biopsy - a significant step forward in their disease management and quality of life outcomes.
Dr James Williams, Managing Director of Resonance Health said: "We are delighted to be involved in the important work being conducted by NERI/TCRN. The program will allow the clinicians involved to gain first-hand experience in the application of FerriScan to patients with thalassemia, and there is the potential for its use in the broader management of other iron loaded patients under their care."
Resonance Health recently announced the signing of a service agreement with Swiss Pharmaceutical company Novartis, a Collaboration Agreement with the DCA Group in Australia and is in discussions with US radiology providers to assist with the commercial roll-out of FerriScan. Completion of these agreements will position FerriScan to be widely accessible to leading clinicians in Australia, the US and Europe. |
Login
